/ mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patients.

Background: Chemotherapy is the preferred treatment in many types of cancer including lung cancer. However, most of patients resist chemotherapy resulting in disease progressive and recurrence. Titin () mutation is proved as a beneficial role in lung squamous carcinoma (LUSC), but the predictive role on chemotherapy resistance of lung cancer is still limited and discussable.

Methods: Clinical information and related somatic mutation profiles were obtained from The Cancer Genome Atlas (TCGA) database and analyzed by R-Studio using R-package. Overall survival (OS) curve and the association between gene mutation and clinical features were determined by GraphPad 6.0 software.

Results: Available data including 563 lung adenocarcinoma (LUAD) and 505 LUSC subjects were included in this study. Among all patients, 205 out of 563 LUAD and 326 out of 505 LUSC patients displayed gene mutation. When comparing the clinical features in -mutated patients to patients without mutation who received chemotherapy, the tumors were always located in the upper lung in LUAD patients with mutation and most of -mutated subjects were at low pathological stage, which was not observed in LUSC patients. However, patients with -mutation, particularly missense mutation, had a higher chemosensitivity and longer OS period than that patients without mutation in both LUAD and LUSC. Of note, LUAD and LUSC patients possessed favorable OS and better chemotherapy response benefiting from /tumor protein 53 (TP53) double mutation compared to and mutation alone, respectively. Additionally, / double mutation-initiated high rate of chemotherapy response were largely concentrated within LUAD and LUSC patients whose anatomic neoplasm subdivision were located in the upper lung.

Conclusions: Collectively, / co-mutation is possibly served as an effective predictor for OS and chemotherapy response in lung cancer.